Kymera Therapeutics(US:KYMR) Globenewswire·2026-03-28 15:00Core Insights - Kymera Therapeutics announced positive results from the BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader for atopic dermatitis, presented at the AAD Annual Meeting [1][2] - The trial demonstrated significant reductions in both biomarkers and clinical measures, indicating the potential of KT-621 to improve treatment options for patients with chronic immuno-inflammatory conditions [2][5] Clinical Trial Results - The BroADen Phase 1b trial involved 22 patients with moderate-to-severe atopic dermatitis, showing deep STAT6 degradation with median reductions of 94% in skin and 98% in blood after 28 days of once-daily dosing [2][5] - Significant reductions in Type 2 inflammatory biomarkers were observed, including a median TARC reduction of 74%, Eotaxin-3 reduction of up to 73%, IL-31 reduction of up to 56%, and IgE reduction of up to 14% [2][5] - Clinical activity results included a mean 63% reduction in EASI, 29% EASI-75, 19% vIGA-AD of 0 or 1, 49% reduction in BSA, and 40% reduction in peak pruritus NRS, indicating improvements in skin lesion severity and itch [2][5] Future Development - Kymera is conducting parallel Phase 2b trials for KT-621 in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late-2027, respectively [3][5] - These trials aim to accelerate the development of KT-621 for subsequent Phase 3 registration studies across multiple Type 2 inflammatory diseases [3][5] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, with a commitment to improving patient outcomes [6] - The company has been recognized as one of Boston's top workplaces and aims to build an industry-leading pipeline of therapies targeting Type 2 inflammatory diseases affecting over 140 million people globally [6][5]